Alnylam Pharmaceuticals, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 8731 https://www.alnylam.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results - Jul 21st, 2021 12:00 pm
Alnylam Pharmaceuticals Stock Sees Healthy Rising Relative Strength Rating - Jul 19th, 2021 7:47 pm
Hedge Funds Aren’t Crazy About Alnylam Pharmaceuticals, Inc. (ALNY) Anymore - Jul 6th, 2021 2:06 pm
Introducing Alnylam Pharmaceuticals (NASDAQ:ALNY), The Stock That Zoomed 176% In The Last Five Years - Jul 5th, 2021 5:32 am
5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now - Jul 1st, 2021 10:56 am
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension - Jun 30th, 2021 11:00 am
Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough - Jun 28th, 2021 2:39 pm
Gene Editing Data Look Good for Intellia. How It Made History. - Jun 28th, 2021 12:39 pm
Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance - Jun 25th, 2021 2:28 pm
This Biotech Is Editing Genes Inside the Body. What It Means for the Stock. - Jun 25th, 2021 8:45 am
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis - Jun 24th, 2021 11:00 am
Alnylam to Host Eighth Annual "RNAi Roundtable" Webcast Series - Jun 23rd, 2021 11:00 am
3 Biotech Stocks With Big Catalysts in June - Jun 22nd, 2021 10:41 am
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting - Jun 7th, 2021 11:30 am
2 Biotech Stocks ARK Invest Bought in June - Jun 7th, 2021 10:25 am
Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy - Jun 1st, 2021 11:00 am
Alnylam to Webcast Presentations at Upcoming June Investor Conferences - May 26th, 2021 8:00 pm
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shift From Loss To Profit - May 21st, 2021 5:52 am
Alnylam Announces New Advances in ATTR Amyloidosis Program - May 11th, 2021 11:00 am
Alnylam to Webcast Presentations at Upcoming May Investor Conferences - May 4th, 2021 12:00 pm